Page 351 - SAHCS HIVMed Journal Vol 20 No 1 2019

Page 8 of 8 Original Research

28. Kappelhoff BS, Rosing H, Huitema AD, et al. Simple and rapid method for the 40. Kikuchi K, Poudel KC, Muganda J, et al. High risk of ART non-adherence and delay
simultaneous determination of the non-nucleoside reverse transcriptase of ART initiation among HIV positive double orphans in Kigali, Rwanda. PLoS One.
inhibitors efavirenz and nevirapine in human plasma using liquid chromatography. 2012;7(7):e41998. https://doi.org/10.1371/journal.pone.0041998
J Chromatogr B Analyt Technol Biomed Life Sci. 2003;792(2):353–362.
41. Martin LR, Williams SL, Haskard KB, et al. The challenge of patient adherence.
29. Duong M, Buisson M, Peytavin G, et al. Low trough plasma concentrations of Ther Clin Risk Manag. 2005;1(3):189–199.
nevirapine associated with virologic rebounds in HIV-infected patients who 42. Stirratt MJ, Dunbar-Jacob, Crane HM, et al. Self-report measures of medication
switched from protease inhibitors. Ann Pharmacother, 2005;39(4):603–609. adherence behavior: Recommendations on optimal use. Transl Behav Med.
https://doi.org/10.1345/aph.1E563 2015;5(4):470–482. https://doi.org/10.1007/s13142-015-0315-2
30. Reddington C, Cohen J, Baldillo A, et al. Adherence to medication regimens among 43. Kunutsor S, Walley J, Katabira E, et al. Clinic attendance for medication refills and
children with human immunodeficiency virus infection. Pediatr Infect Dis J. medication adherence amongst an antiretroviral treatment cohort in Uganda:
2000;19(12):1148–1153. A prospective study. AIDS Res Treat, 2010;2010:872396. https://doi.org/10.
31. Van Dyke RB, Lee S, Johnson GM, et al. Reported adherence as a determinant of 1155/2010/872396
response to highly active antiretroviral therapy in children who have human 44. Ugwu R, Eneh A. Factors influencing adherence to paediatric antiretroviral
immunodeficiency virus infection. Pediatrics. 2002;109(4):e61. therapy in Portharcourt, South- South Nigeria. Pan Afr Med J. 2013;16:30. https://
32. Bossi P, Peytavin G, Ait-Mohand H, et al. GENOPHAR: A randomized study of doi.org/10.11604/pamj.2013.16.30.1877
plasma drug measurements in association with genotypic resistance testing and 45. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-
expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Saharan Africa and North America: A meta-analysis. JAMA. 2006;296(6):679–690.
Med. 2004;5(5):352–359. https://doi.org/10.1111/j.1468-1293.2004.00234.x https://doi.org/10.1001/jama.296.6.679
33. DiMatteo MR. Variations in patients’ adherence to medical recommendations: 46. Tiyou A, Belachew T, Alemseged F, et al. Predictors of adherence to antiretroviral
A quantitative review of 50 years of research. Med Care. 2004;42(3):200–209. therapy among people living with HIV/AIDS in resource-limited setting of
34. Gunda DW, Kasang C, Kidenya BR, et al. Plasma concentrations of efavirenz and southwest Ethiopia. AIDS Res Ther. 2010;7:39. https://doi.org/10.1186/1742-
6405-7-39
nevirapine among HIV-infected patients with immunological failure attending a
tertiary hospital in North-western Tanzania. PLoS One. 2013;8(9):e75118. https:// 47. Posse M, Meheus F, Van Asten H, et al. Barriers to access to antiretroviral
doi.org/10.1371/journal.pone.0075118 treatment in developing countries: A review. Trop Med Int Health. 2008;13(7):
904–913. https://doi.org/10.1111/j.1365-3156.2008.02091.x
35. Boehringer Ingelheim Pharmaceuticals Inc. Nevirapine (Viramines) Product
Monography. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc.; 2004. 48. Wasti SP, Van Teijlingen E, Simkhada P, et al. Factors influencing adherence to
antiretroviral treatment in Asian developing countries: A systematic review. Trop
36. Cooper CL, Van Heeswijk, RP. Once-daily nevirapine dosing: A pharmacokinetics, Med Int Health. 2012;17(1):71–81. https://doi.org/10.1111/j.1365-3156. 2011.
efficacy and safety review. HIV Med. 2007;8(1):1–7. https://doi.org/10. 1111/j. 02888.x
1468-1293.2007.00426.x
49. Olowookere SA, Fatiregun AA, Ladipo MM-A, et al. Reducing waiting time at a
37. Arage G, Tessema GA, Kassa H. Adherence to antiretroviral therapy and its Nigerian HIV treatment clinic: Opinions from and the satisfaction of people living
associated factors among children at South Wollo Zone Hospitals, Northeast with HIV/AIDS. J Int Assoc Physicians AIDS Care (Chic). 2012;11(3):188–191.
Ethiopia: A cross-sectional study. BMC Public Health. 2014;14(1):365. https://doi. https://doi.org/10.1177/1545109711402214
org/10.1186/1471-2458-14-365 50. Hardon AP, Akurut D, Comoro C, et al. Hunger, waiting time and transport costs:
38. Wadunde I, Tuhebwe D, Ediau M, et al. Factors associated with adherence to Time to confront challenges to ART adherence in Africa. AIDS Care.
antiretroviral therapy among HIV infected children in Kabale district, Uganda: 2007;19(5):658–665. https://doi.org/10.1080/09540120701244943
A cross sectional study. BMC Res Notes. 2018;11(1):466. https://doi.org/10.1186/ 51. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality
s13104-018-3575-3 among patients with advanced human immunodeficiency virus infection. HIV
39. Dachew BA, Tesfahunegn TB, Birhanu AM. Adherence to highly active antiretroviral outpatient study investigators. N Engl J Med. 1998;338(13):853–860. https://doi.
therapy and associated factors among children at the University of Gondar org/10.1056/NEJM199803263381301
Hospital and Gondar Poly Clinic, Northwest Ethiopia: A cross-sectional institutional 52. Bertagnolio S, De Luca A, Vitoria M, et al. Determinants of HIV drug resistance and
based study. BMC Public Health. 2014;14:875. https://doi.org/10.1186/1471- public health implications in low- and middle-income countries. Antivir Ther.
2458-14-875 2012;17(6):941–953. https://doi.org/10.3851/IMP2320

http://www.sajhivmed.org.za 344 Open Access